You are here

Brain Dev DOI:10.1016/j.braindev.2020.04.008

Successful treatment of intractable epilepsy with ketogenic diet therapy in twins with ALG3-CDG.

Publication TypeJournal Article
Year of Publication2020
AuthorsPaketci, C, Edem, P, Hiz, S, Sonmezler, E, Soydemir, D, G Uzan, S, Oktay, Y, O'Heir, E, Beltran, S, Laurie, S, Töpf, A, Lochmuller, H, Horvath, R, Yis, U
JournalBrain Dev
Date Published2020 May 07
ISSN1872-7131
Abstract

BACKGROUND: Congenital disorders of glycosylation (CDG) is a heterogeneous group of congenital metabolic diseases with multisystem clinical involvement. ALG3-CDG is a very rare subtype with only 24 cases reported so far.

CASE: Here, we report two siblings with dysmorphic features, growth retardation, microcephaly, intractable epilepsy, and hemangioma in the frontal, occipital and lumbosacral regions.

RESULTS: We studied two siblings by whole exome sequencing. A pathogenic variant in ALG3 (NM_005787.6: c.165C > T; p.Gly55=) that had been previously associated with congenital glycolysis defect type 1d was identified. Their intractable seizures were controlled by ketogenic diet.

CONCLUSION: Although prominent findings of growth retardation and microcephaly seen in our patients have been extensively reported before, presence of hemangioma is a novel finding that may be used as an indication for ALG3-CDG diagnosis. Our patients are the first reported cases whose intractable seizures were controlled with ketogenic diet. This report adds ketogenic diet as an option for treatment of intractable epilepsy in ALG3-CDG.

DOI10.1016/j.braindev.2020.04.008
Pubmed

http://www.ncbi.nlm.nih.gov/pubmed/32389449?dopt=Abstract

Alternate JournalBrain Dev.
PubMed ID32389449